Psychopharmacoepidemiology: Scope and Application

精神藥物流行病學的研究範疇與應用

10.29478/TJP.200803.0002

張明永(Mian-Yoon Chong)

精神藥物流行病學 ； 藥物流行病學 ； 處方行為 ； 藥物使用概況 ； Psychopharmacoepidemiology ； pharmacoepidemiology of psychotropic drugs ； prescribing behavior ； drug utilization

台灣精神醫學

22卷1期（2008 / 03 / 01）

3 - 15

英文

藥物治療是目前最常醫療處置，尤其是精神科的治療。超過一半以上的藥物嚴重副作用是在核准上市後被發現的；因此，為了確保藥物的安全性，藥物上市後的研究尤其來的重要。透過精神藥物流行病學，可以有效的對上市後之抗精神藥物的監控及其風險與效益的研究，探討抗精神藥物是如何的處方、應用、以及影響其處方及預後的種種因素。本綜說簡介精神藥物流行病學的發展，特別是研究的範疇、限制、應用與將來的展望。

The most common therapeutic intervention in medicine is the writing of a prescription. It is especially true in psychiatry as pharmacotherapy has become its mainstay treatment. With over half of the approved drugs having serious adverse effects that were not detected before the approval, it is therefore important to study post-marketing drugs in order to ensure the safety of a drug. The benefits and risks of a psychotropic drug could be studied through using psycho pharmaco epidemiological methods, a science underlying post-marketing drug surveillance. It delineates how psychotropic drugs are prescribed and utilized, investigates reasons underlying prescriptions, and assesses outcomes and variables which may affect these outcomes. This review covers the introduction and development of psycho pharmaco epidemiology, specifically to its scope and limitation, examples of studies published in the past years, and its future perspectives.

1. (1991).Triazolam's status in European Community.Lancet,338,1586-1587.
2. (1992).Triazolam hearing.Lancet,339,1291.
3. Ananth J,Parameswaran S,Gunatilake S(2003).Antipsychotic polypharmacy.Curr Pharm Design,16,713-718.
4. Andrews G,Sanderson K,Corry J,Issakidis C,Lapsley H(2003).Cost-effectiveness of current and optimal treatment for schizophrenia.Br J Psychiatry,183,427-435.
5. Awad AG(2004).Antipsychotic medications: compliance and attitudes towards treatment.Curr Opin Psychiat,17,75-80.
6. Ayd FJ(1991).The early history of modern psychopharmacology.Neuropsychopharmacol,5,71-84.
7. Baron JA,Barrett J(1994).Utility and Limitations of claims data.Annals of InternalMedicine,120,1049-1051.
8. Basu A(2004).Cost-effectiveness analysis of pharmacological treatments in schizophrenia: critical review of results and methodological issues.Schizophr Res,71,445-462.
9. Beasley CM,Dornseif BE,Bosomworth JC(1991).Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression.BMJ,303,685-692.
10. Begaud B(2000).Dictionary of Pharmacoepidemiology.Chichester:John Wiley and Sons.
11. Blackwell B(1976).Treatment adherence.Br J Psychiatry,128,513-531.
12. Bowers L,Callangan P,Clark N,Evers C(2004).Comparisons of psychotropic drug prescribing patterns in acute psychiatric wards across Europe.Eur J Clin Pharmacol,60,29-35.
13. Brahams D(1991).Triazolam suspended.Lancet,338,938.
14. Breen R,Thronhill JT(1998).Noncompliance with medications for psychiatric disorders: reasons and remedies.CNS Drugs,9,457-471.
15. Chien IC,Chou YJ,Lin CH,Bih SH,Chou P(2004).Prevalence of psychiatric disorders among National Health Insurances enrollees in Taiwan.Psychiatr Serv,55,691-697.
16. Chong MY,Tan CH,Fujii S(2004).Antipsychotic drug prescription for Schizophrenia in East Asia: A rationale for change.Psychiat Clin Neuro,58,61-67.
17. Cole JO(1988).Where are those new antidepressants we were promised?.Arch Gen Psychiatry,45,193-197.
18. Curtis LH,Masselink LE,stbye T(2005).Prevalence of atypical antipsychotic drug use among commercially insured youths in the United States.Arch Pediatr Adolesc Med,159,362-366.
19. Dams PE(1993).Looking for answers in all the wrong places.Ann Intern Med,119,855-857.
20. Famuyiwa OO(1983).Psychotropic drug prescription in Nigeria.Acta Psychiatr Scand,68,73-81.
21. Fiaolova D,Topinkova E,Gambassi G(2005).Potentially inappropriate medication use among elderly home care patients in Europe.JAMA,293,1348-1358.
22. Fisher ES,Whaley FS,Krushat WM(1992).The accuracy of Medicare's hospital claims data: progress has been made, but problems remain.Am J Pub Health,82,243-248.
23. Grauer DW,Lee J,Odom TD(2003).Pharmacoeconomics and Outcomes: Applications for Patient Care.Kansas City:American College of Clinical Pharmacy.
24. Grohmann R,Engel RR,Geissler KH,Ruther E(2004).Psychotropic drug use in psychiatric inpatients: recent trends and changes over time-data from the AMSP study.Pharmacopsychiatry,37(1),27-38.
25. Hamann J,Ruppert A,Auby P,Pugner K,Kissling W(2003).Antipsychotic prescribing patterns in Germany: a retrospective analysis using a large outpatient prescription database.Int Clin Psychopharm,18,237-242.
26. Hemminki E,Ghodse H,Khan I (eds.)(1988).Psychoactive Drugs: Improving Prescribing Practices.Geneva:WHO.
27. Higgins N,Howard L(2005).Database use in psychiatric research: an international review.Eur J Psychiat,19,19-30.
28. Jollis JG,Ancukiewicz M,DeLong ER,Pryor DB,Muhlbaier LH,Mark DB(1993).Discordance of databases designed for claims payment versus clinical information systems: implications for outcomes research.Ann Int Med,119,844-850.
29. Joyce CRB,Last JM,Weatherall M(1968).Personal factors as a cause of differences in prescribing by general practitioners.Br J Prev Soc Med,22,170-177.
30. Karow A,Lambert M(2003).Polypharmacy in treatment with psychotropic drugs: the underestimated phenomenon: Curr Opin Psychiat,16,713-718.
31. Kingsbury SJ,Yi D,Simpson GM(2001).Rational and irrational polypharmacy.Psychiat Serv,52,1033-1035.
32. Kuhn R(1958).The treatment of depressive states with G22355 (imipramine hydrochloride).Am J Psychiatry,115,459-464.
33. Lacro J,Dunn L,Dolder C(2002).Prevalence of and risk factors for medication non-adherence in patient with schizophrenia: a comprehensive review of recent literature.J Clin Psychiat,63,892-908.
34. Lawson DH(1984).Pharmacoepidemiology: a new discipline.BMJ,289,940-941.
35. Lee JAH,Draper PA,Weatherall M(1965).Prescribing in three English towns.Milbank Mem Fund Q,43,285-290.
36. Leufkens HG,Urquhart J(1994).Variability in patterns of drug usage.J Pharm Pharmacol,46(1),434-437.
37. Linden M,Thiels C(2001).Epidemiology of prescriptions for neuroleptic drugs: tranquilizers rather than antipsychotics.Pharmacopsychiatry,34,150-154.
38. Magliano L,Fiorillo A,Guarneri M(2004).Prescription of psychotropic drugs to patients with schizophrenia: an Italian national survey.Eur J Clin Pharmacol,60,513-522.
39. Martin K,Begaud B,Latry P(2004).Differences between clinical trials and post-marketing use.Brit J Clin Pharmacol,57,86-92.
40. McBride WG(1961).Thalidomide and congenital abnormalities.Lancet.
41. Meade TW(1967).Prescribing of chloramphenicol in general practice.Br Med J,1,671-674.
42. Mehrez A,Gafni A(1989).Quality-adjusted Life Years, Utility Theory, and Healthy-years Equivalents.Med Decis Making,9,142-149.
43. Meyboom RHB,Strom BL,Velo GP (eds.)(1992).Drug Epidemiology and Postmarketing Drug Surveillance.New York:Plenum.
44. Miller AL,Craig CS(2002).Combination antipsychotics: Pros, cons and questions.Schizophrenia Bull,28,108-109.
45. Moore N,Hall G,Sturkenboom M,Mann R,Lagnaoui R,Begaud B(2003).Biases affecting the proportional reporting ratio (PRR) in spontaneous reports pharmacovigilance databases: the example of sertindole.Pharmacoepidem Dr,12,271-281.
46. Morris HH,Estes M(1987).Travelers amnesia: transient global amnesia secondary to triazolam.JAMA,258,945-946.
47. Muijen M,Silverstone T(1987).A comparative hospital survey of psychotropic drug prescribing.Br J Psychiatry,150,501-504.
48. Muller C(1965).Medical review of prescribing.J Chronic Dis,18,689-696.
49. Muller C(1968).Outpatient drug prescribing related to clinic utilization in four New York City hospitals.Health Serv Res,3,142-154.
50. Oehl M,Hummer M,Fleischhacker WW(2000).Compliance with antipsychotic treatment.Acta Psychiatr Scand,102(407),83-86.
51. Parish, P(1973).Drug prescribing: the concern of all.J Roy Soc Health,4,213-217.
52. Parry HJ,Balter MB,Mellinger GD(1973).National patterns of psychotherapeutic drug use.Arch Gen Psychiatry,28,796-783.
53. Patton C,Gill-Banham S(2003).Prescribing errors in psychiatry.Psychiat Bull,27,208-210.
54. Pincus HA,Tanielian TL,Marcus SC(1998).Prescribing trends in psychotropic medications: Primary care, psychiatry and other medical specialties.JAMA,279,526-531.
55. Ray WA,Griffin MR,Avorn J(1993).Evaluating drugs after their approval for clinical use.New Engl J Med,329,2029-2032.
56. Shen WW(1999).A history of antipsychotic drug development.Compr Psychiatry,40,407-414.
57. Sim K,Su A,Fujii S(2001).Antipsychotic polypharmacy in patients with schizophrenia: A multicentre comparative study in East Asia.Brit J Clinl Pharmaco,58,178-183.
58. Sim K,Su A,Ungvari G(2004).Depot antipsychotic use in schizophrenia: an East Asian perspective.Hum Psychopharm,19,103-109.
59. Sloan FA(1996).Valuating Health Care: Cost, Benefits, and Effectiveness of Pharmaceuticals and other Medical Technologies.London:Cambridge University Press.
60. Sternbach LH(1980).The Benzodiazepine Story.Basle, Switzerland:Editiones.
61. Strom BL(2000).Pharmacoepidemiology.Chichester:John Wiley and Sons Ltd.
62. Taylor D,Mir S,Kerwin R(2000).Prescribing in schizophrenia: Psychiat Bull,24,106-108.
63. Teicher MH,Glod C,Cole JO(1990).Emergence of intense suicidal preoccupation during fluoxetine treatment.Am J Psychiatry,147,207-210.
64. Tognoni G(1999).Pharmacoepidemiology of psychotropic drugs in patients with severe mental disorders in Italy.Eur J Clin Pharmacol,55,685-690.
65. Urquhart J(1992).Time to take our medicines, seriously.Pharm Weekly,127,769-776.
66. Van Putten T(1974).Why do schizophrenic patients refuse to take their drugs?.Arch Gen Psychiatry,31,67-72.
67. Velligan DI,Lam F,Ershefsky L,Miller AI(2003).Perspectives on medication adherence and atypical antipsychotic medications.Psychiatr Serv,54,665-667.
68. Verdoux H,Begaud B(2004).Pharmacoepidemiology: what do (and don't) we know about utilization and impact of psychotropic medications in real-life conditions?.Br J Psychiatry,185,93-94.
69. Wallerstein RO,Condit PK,Kasper CK,Brown JW,Morrison FR(1969).Statewide study of chloramphenicol therapy and aplastic anemia.J Am Med Assoc,208,2045-2050.
70. Walley T,Haycox A,Boland A(2003).Pharmacoeconomics.London:Churchill Livingstone.
71. Wang PS,Schneeweiss,Avorn J(2003).Recent developments in psychopharmacoepidemiology.Curr Opin Psychiatry,16,719-724.
72. Wilson,WH,Ban TA,GuyW(1985).Pharmacotherapy of chronic hospitalized schizophrenics: prescription practices.Neuropsychobiology,14,75-82.
73. Yang SY(2007).Unpublished PhD Thesis of the Graduate Institute of Medicine.Kaohsiung, Taiwan:Kaohsiung Medical University.
74. Yang SY,Yan YHK,Yang YH,ChongMY,Lai CS(2007).Antipsychotic drug-induced involuntary movement disorders: a four-year inpatients survey in Taiwan.Clin Pharmacol Ther,81,586-594.
75. Yildiz M Cerit C(2004).Antipsychotic drug use pattern for patients with schizophrenia in an outpatient clinic in Turkey: A retrospective study.Int J Psychiat Clin,8,41-45.
76. Zito JM,Safer DJ,dosReis S,Gardner JF,Boles M,Lynch F(2000).Trends in the prescribing of psychotropic medications to preschoolers.JAMA,283,1025-1030.